Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204406568> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W3204406568 abstract "Abstract Background Diabetic kidney disease (DKD) is considered a major cause of end stage renal disease (ESRD). It has been established that controlling microalbuminuria can delay progression to ESRD. Sodium glucose co transporter 2 inhibitor (SGLT2 i) is a newer antidiabetic drug that has a renoprotective and antiproteinuric effect. Aim of the Study to study the effect of SGLT2 inhibitor on proteinuria in diabetic patients and compare it with classic antiproteinuric drugs. Patients and Methods we conducted a randomized interventional study, involving 60 adult patients with type 2 DM divided into 2 groups: group I were prescribed the classic antiproteinuric drugs in the form of ACE inhibitors or ARBs, aspirin and statins and group II were prescribed an additional dapagliflozin 10 mg/day. Follow up as regard changes in UACR, HbA1C, Blood pressure, body weight and e GFR was done after 6 months of treatment. Results There was statistically significant decline in UACR after 6 months of treatment with dapagliflozin in group II in comparison to group I (p-value < 0.001). There was also statistically significant decline in SBP in both groups with (p-value < 0.010) in group I and (p-value <0.001) in group II and there was significant decline in DBP in both groups (p-value < 0.001). HbA1c decreased significantly in both groups, (p-value <0.023) in group I and (p-value <0.001) in group II. We also noted a significant reduction of body weight in group II (p-value <0.001). There was a statistically significant negative correlation between the change in UACR and the change in e GFR. Conclusion There was better reduction in albuminuria when adding dapagliflozin to antiproteinuric drugs, so we recommend starting dapagliflozin early in patients with DKD to delay progreesion to ESRD." @default.
- W3204406568 created "2021-10-11" @default.
- W3204406568 creator A5017194157 @default.
- W3204406568 creator A5022581803 @default.
- W3204406568 creator A5067205365 @default.
- W3204406568 creator A5071884804 @default.
- W3204406568 creator A5079127362 @default.
- W3204406568 creator A5080776934 @default.
- W3204406568 date "2021-10-01" @default.
- W3204406568 modified "2023-10-15" @default.
- W3204406568 title "EFFECT OF SODIUM GLUCOSE CO TRANSPORTER 2 INHIBITOR ON PROTEINURIA IN DIABETIC PATIENTS" @default.
- W3204406568 doi "https://doi.org/10.1093/qjmed/hcab100.144" @default.
- W3204406568 hasPublicationYear "2021" @default.
- W3204406568 type Work @default.
- W3204406568 sameAs 3204406568 @default.
- W3204406568 citedByCount "0" @default.
- W3204406568 crossrefType "journal-article" @default.
- W3204406568 hasAuthorship W3204406568A5017194157 @default.
- W3204406568 hasAuthorship W3204406568A5022581803 @default.
- W3204406568 hasAuthorship W3204406568A5067205365 @default.
- W3204406568 hasAuthorship W3204406568A5071884804 @default.
- W3204406568 hasAuthorship W3204406568A5079127362 @default.
- W3204406568 hasAuthorship W3204406568A5080776934 @default.
- W3204406568 hasBestOaLocation W32044065681 @default.
- W3204406568 hasConcept C126322002 @default.
- W3204406568 hasConcept C126894567 @default.
- W3204406568 hasConcept C134018914 @default.
- W3204406568 hasConcept C159641895 @default.
- W3204406568 hasConcept C2776174234 @default.
- W3204406568 hasConcept C2777180221 @default.
- W3204406568 hasConcept C2777422806 @default.
- W3204406568 hasConcept C2777628954 @default.
- W3204406568 hasConcept C2779561371 @default.
- W3204406568 hasConcept C2779922275 @default.
- W3204406568 hasConcept C2780091579 @default.
- W3204406568 hasConcept C2781203188 @default.
- W3204406568 hasConcept C555293320 @default.
- W3204406568 hasConcept C71924100 @default.
- W3204406568 hasConcept C84393581 @default.
- W3204406568 hasConceptScore W3204406568C126322002 @default.
- W3204406568 hasConceptScore W3204406568C126894567 @default.
- W3204406568 hasConceptScore W3204406568C134018914 @default.
- W3204406568 hasConceptScore W3204406568C159641895 @default.
- W3204406568 hasConceptScore W3204406568C2776174234 @default.
- W3204406568 hasConceptScore W3204406568C2777180221 @default.
- W3204406568 hasConceptScore W3204406568C2777422806 @default.
- W3204406568 hasConceptScore W3204406568C2777628954 @default.
- W3204406568 hasConceptScore W3204406568C2779561371 @default.
- W3204406568 hasConceptScore W3204406568C2779922275 @default.
- W3204406568 hasConceptScore W3204406568C2780091579 @default.
- W3204406568 hasConceptScore W3204406568C2781203188 @default.
- W3204406568 hasConceptScore W3204406568C555293320 @default.
- W3204406568 hasConceptScore W3204406568C71924100 @default.
- W3204406568 hasConceptScore W3204406568C84393581 @default.
- W3204406568 hasIssue "Supplement_1" @default.
- W3204406568 hasLocation W32044065681 @default.
- W3204406568 hasOpenAccess W3204406568 @default.
- W3204406568 hasPrimaryLocation W32044065681 @default.
- W3204406568 hasRelatedWork W1992690695 @default.
- W3204406568 hasRelatedWork W2041854617 @default.
- W3204406568 hasRelatedWork W2059141440 @default.
- W3204406568 hasRelatedWork W2077477582 @default.
- W3204406568 hasRelatedWork W2353324822 @default.
- W3204406568 hasRelatedWork W2376102491 @default.
- W3204406568 hasRelatedWork W2729727703 @default.
- W3204406568 hasRelatedWork W3119567526 @default.
- W3204406568 hasRelatedWork W3186157638 @default.
- W3204406568 hasRelatedWork W3202330513 @default.
- W3204406568 hasVolume "114" @default.
- W3204406568 isParatext "false" @default.
- W3204406568 isRetracted "false" @default.
- W3204406568 magId "3204406568" @default.
- W3204406568 workType "article" @default.